Research outlook

Where esophageal squamous cell cancer treatment is heading

Esophageal squamous cell carcinoma · Updated Nov 12, 2026

Immunotherapy plus chemotherapy is the standard first treatment. After it stops working, options are thin, and that is where most new drugs are aimed.

  1. Now

    Nov 2026

    Immunotherapy plus chemo comes firstHappened +7 months survival

    PD-1 immunotherapy plus chemotherapy is the first treatment for advanced disease.

    +7 months: typical survival with tislelizumab added, 16.8 vs 9.6 months.

    Iza-bren as second treatment, ChinaHappened 36% lower risk of death

    Iza-bren, a targeted drug-carrying antibody, beat chemotherapy as a second treatment and was approved in China.

    36% lower: risk of death vs chemotherapy, 9.8 vs 7.2 months.

    Immunotherapy with chemoradiationHappened 15.2 vs 14.7 months, no gain

    Adding immunotherapy to curative chemoradiation missed its goal in two large trials.

    15.2 vs 14.7: months before the cancer returned, with vs without pembrolizumab.

  2. 6 months

    by May 2027

    Iza-bren enters China's guidelinesLikely 4.2 vs 2.0 months before growth

    Iza-bren enters China's treatment guidelines. An expert consensus on how to use it is already published.

    4.2 vs 2.0: months before the cancer grew, iza-bren vs chemotherapy.

    KC1036 pill trial finishesPossible 30% of tumors shrank

    KC1036, a pill tested against chemotherapy as a third treatment in 490 people, reaches its completion date.

    30%: of tumors shrank in an early trial, 8 of 27 people.

    First results on holding back surgeryLong shot 74% vs 71% alive at 2 years

    First results from NEEDS, a 1,020-person trial asking whether surgery can be held in reserve after chemoradiation.

    74% vs 71%: alive at 2 years, watching vs surgery, in the Dutch SANO trial (both esophageal cancer types).

  3. 12 months

    by Nov 2027

    Immunotherapy around surgeryPossible 28% vs 5% tumors cleared

    Survival results from a large trial of immunotherapy before and after surgery (toripalimab, 663 people).

    28% vs 5%: of tumors fully cleared before surgery with a similar drug. Survival effect not yet known.

    Durvalumab with chemoradiationPossible 31% lower risk of death, unconfirmed

    KUNLUN reports on durvalumab given with chemoradiation. Two similar trials missed, so a clear win would be a surprise.

    31% lower: risk of death with atezolizumab after chemoradiation, a signal the trial could not confirm.

    Ivonescimab's first results herePossible 27% lower risk of death, lung cancer

    First results in this cancer for ivonescimab, an immunotherapy that beat pembrolizumab in lung cancer.

    27% lower: risk of death vs pembrolizumab in lung cancer, 30.8 vs 22.6 months.

  4. 3 years

    by late 2029

    Another conjugate beats chemoLikely 41% of tumors shrank

    At least one more antibody-drug conjugate beats chemotherapy in phase 3. Six such trials are running.

    41%: of tumors shrank with YL201 across several cancers, 287 people.

    One reaches the US, Europe or JapanPossible 21% of tumors shrank

    One becomes available in the US, Europe or Japan. The worldwide I-DXd trial finishes around mid-2028.

    21%: of tumors shrank with I-DXd in an early trial, 6 of 28 heavily treated people.

    Conjugate plus immunotherapy firstLong shot

    First phase 3 results for these drugs combined with immunotherapy as the first treatment.

  5. 5 years

    by late 2031

    Watching instead of operatingPossible 74% vs 71% alive at 2 years

    Watching instead of operating becomes an accepted choice for people whose tumor disappears after initial treatment.

    74% vs 71%: alive at 2 years, watching vs surgery, in the Dutch SANO trial.

    Conjugates replace platinum chemoLong shot

    An antibody-drug conjugate plus immunotherapy replaces platinum chemotherapy as the first treatment.

    Blood test guides post-surgery careLong shot

    Blood tests for leftover tumor DNA decide who needs more treatment after surgery.

Happened Likely Possible Long shot

The research paths

Heating up

Antibody-drug conjugates after immunotherapy

36% lower risk of death
Details and 7 trialsHide

These drugs attach chemotherapy to an antibody that seeks out tumor cells. Iza-bren proved the idea in 2026. Six more phase 3 trials are testing others against the same chemotherapy, most aimed at a protein called B7-H3.

WatchI-DXd is the only one run worldwide, including the US, so it is the most likely route to an option outside China.

Early

Antibody-drug conjugates as the first treatment

Details and 2 trialsHide

The next step is pairing these drugs with immunotherapy up front, in place of platinum chemotherapy. Two trials have started. Side effects are the open question: serious ones were more common with iza-bren than with chemotherapy (85% vs 60%).

WatchWhether the combinations are tolerable enough to give for many months.

Maturing

Immunotherapy before surgery

28% vs 5% tumors cleared
Details and 3 trialsHide

Adding immunotherapy to pre-surgery chemotherapy clears the tumor completely more often (28% vs 5% in ESCORT-NEO). Whether that means people live longer is not yet proven. The trials below are designed to answer that.

WatchSurvival data, and whether immunotherapy can replace radiation before surgery.

Building

Avoiding surgery

74% vs 71% alive at 2 years
Details and 3 trialsHide

Esophagectomy is a major operation. Several large trials ask whether people whose tumor responds well can keep their esophagus and have surgery only if the cancer returns.

WatchNEEDS is the largest and reports first. A result showing no survival penalty would change practice in Europe quickly.

Cooling

Immunotherapy with curative chemoradiation

15.2 vs 14.7 months, no gain
Details and 4 trialsHide

For people who cannot have surgery, the hope was that immunotherapy would make chemoradiation cure more often. KEYNOTE-975 (pembrolizumab) and SKYSCRAPER-07 (tiragolumab plus atezolizumab) both missed their main goals.

WatchKUNLUN is the last large global trial. Atezolizumab alone showed a survival signal in SKYSCRAPER-07 that could not be formally tested.

Long horizon

Earlier detection and basic biology

DetailsHide

NIH funding here is small and aimed upstream: why these tumors form (NRF2, mutant p53, alcohol and ALDH2), a low-cost point-of-care test for low-income countries, and a blood test based on DNA methylation. None of this reaches patients inside five years, but it shapes what comes after.

WatchJohns Hopkins point-of-care diagnosis project (funded through 2028).

Borrowed from other cancers

From Nasopharyngeal and triple-negative breast cancer

Iza-bren

36% lower risk of death Approved in China

Antibody-drug conjugate aimed at EGFR and HER3. Won phase 3 trials in all three cancers.

From Small cell lung cancer

I-DXd (ifinatamab deruxtecan)

52% and 21% of tumors shrank Phase 3

Antibody-drug conjugate aimed at B7-H3. Now in a worldwide phase 3 here and in first-treatment combinations.

From Breast and lung cancer

Sacituzumab tirumotecan

Phase 2

Antibody-drug conjugate aimed at TROP2. Merck is testing it here after immunotherapy and as part of the first treatment.

From Lung cancer

Ivonescimab

27% lower risk of death, lung cancer Phase 2

One antibody that blocks both PD-1 and VEGF. Five small trials here, before surgery and for advanced disease.

From Cervical and stomach cancer

Cadonilimab

81% of tumors shrank Phase 2/3

One antibody that blocks both PD-1 and CTLA-4. Its maker is running a randomized trial around surgery.

From Head and neck squamous cancer

Petosemtamab

50% lower risk of death, head and neck Phase 1/2

Antibody aimed at EGFR and LGR5. Head and neck tumors are close biological relatives of this cancer; esophageal cancer is included in its multi-cancer trial.

From Bladder cancer

Enfortumab vedotin

Phase 2

Antibody-drug conjugate aimed at nectin-4. A multi-cancer trial that included esophageal tumors has finished collecting data.

From Melanoma

Personalized cancer vaccines

Phase 2

A vaccine built from each person's tumor mutations, given with immunotherapy after chemoradiation. Randomized, 165 people.

Open to join now

See every recruiting ESCC trial →

When the large trials finish

Completion dates the trials registered. Results usually follow 3 to 12 months later.

2026202720282029203020312032Today
Chemoradiation with surgery only if needed (NEEDS)Avoiding surgery
Dec 2026
Toripalimab before and after surgeryImmunotherapy before surgery
May 2027
Durvalumab + chemoradiation (KUNLUN)Immunotherapy with curative chemoradiation
Jun 2027
Surgery vs chemoradiation after endoscopic removal (Ad-ESD)Avoiding surgery
Dec 2027
YL201 (TAISHAN-303)Antibody-drug conjugates after immunotherapy
Apr 2028
I-DXd (IDeate-Esophageal01)Antibody-drug conjugates after immunotherapy
Jun 2028
QLC5508Antibody-drug conjugates after immunotherapy
Jun 2028
SYS6010Antibody-drug conjugates after immunotherapy
Dec 2028
Iza-bren + tislelizumab (PANKU-Esophagus02)Antibody-drug conjugates as the first treatment
Dec 2028
Camrelizumab + chemo or chemoradiation (NICE-2)Immunotherapy before surgery
Dec 2028
PD-1 maintenance after chemoradiationImmunotherapy with curative chemoradiation
Feb 2029
FH-006Antibody-drug conjugates after immunotherapy
Jun 2029
SYS6010 + enlonstobartAntibody-drug conjugates as the first treatment
Dec 2029
HS-20093Antibody-drug conjugates after immunotherapy
Dec 2030
Sintilimab + chemoradiation (NEOCRTEC2101)Immunotherapy before surgery
Jan 2031
Proton vs standard radiation (NRG-GI006)Immunotherapy with curative chemoradiation
Nov 2031
Surgery vs chemoradiation after a good responseAvoiding surgery
Mar 2032

Knowledge on the way

Not treatments yet: detection, causes and how care is delivered. Mostly NIH-funded.

What just happened

Pembrolizumab added to chemoradiation did not help

KEYNOTE-975, 703 people. Time without the cancer returning was 15.2 vs 14.7 months (hazard ratio 0.97). The trial was stopped.

Iza-bren approved in China as a second treatment

PANKU-Esophagus01, 497 people. Typical survival 9.8 vs 7.2 months with chemotherapy (hazard ratio 0.64). Serious side effects 85% vs 60%.

FDA cleared a PD-L1 test to select patients for pembrolizumab

Confirms the US shift to giving first-line immunotherapy only when the tumor tests PD-L1 positive.

Tiragolumab plus atezolizumab after chemoradiation missed

SKYSCRAPER-07. Atezolizumab alone showed a survival signal (hazard ratio 0.69) that the trial design did not allow to be formally tested.

FDA approved tislelizumab plus chemotherapy as first treatment

RATIONALE-306. In PD-L1 positive tumors, typical survival was 16.8 vs 9.6 months (hazard ratio 0.66).

Immunotherapy before surgery cleared more tumors

ESCORT-NEO. Complete tumor clearance 28% with camrelizumab plus chemotherapy vs 4.7% with chemotherapy. Survival data still maturing.

Standard treatment today

How to read this page, and sourcesHow to read this page, and sources

See ESCC trials recruiting now →

Last reviewed 2026-11-12 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.